menu
    • menu
    [{"orgOrder":0,"company":"PIQUR Therapeutics","sponsor":"University Hospital, Basel | Insel Gruppe AG, University Hospital Bern | University Hospital Z\u00fcrich","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Bimiralisib","moa":"phosphatidylinositol 3-kinase inhibitors","graph1":"Oncology","graph2":"Phase II","graph3":"PIQUR Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"PIQUR Therapeutics \/ University Hospital, Basel | Insel Gruppe AG, University Hospital Bern | University Hospital Z\u00fcrich","highestDevelopmentStatusID":"8","companyTruncated":"PIQUR Therapeutics \/ University Hospital, Basel | Insel Gruppe AG, University Hospital Bern | University Hospital Z\u00fcrich"},{"orgOrder":0,"company":"PIQUR Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Bimiralisib","moa":"phosphatidylinositol 3-kinase inhibitors","graph1":"Oncology","graph2":"Phase II","graph3":"PIQUR Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PIQUR Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"PIQUR Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"PIQUR Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Bimiralisib","moa":"phosphatidylinositol 3-kinase inhibitors","graph1":"Oncology","graph2":"Phase II","graph3":"PIQUR Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PIQUR Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"PIQUR Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"PIQUR Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Bimiralisib","moa":"phosphatidylinositol 3-kinase inhibitors","graph1":"Oncology","graph2":"Phase I","graph3":"PIQUR Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PIQUR Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"PIQUR Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"PIQUR Therapeutics","sponsor":"University Hospital, Basel | University Hospital Munich | University Hospital Freiburg | Charite University, Berlin, Germany | University of Stuttgart","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Bimiralisib","moa":"phosphatidylinositol 3-kinase inhibitors","graph1":"Oncology","graph2":"Phase II","graph3":"PIQUR Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PIQUR Therapeutics \/ University Hospital, Basel | University Hospital Munich | University Hospital Freiburg | Charite University, Berlin, Germany | University of Stuttgart","highestDevelopmentStatusID":"8","companyTruncated":"PIQUR Therapeutics \/ University Hospital, Basel | University Hospital Munich | University Hospital Freiburg | Charite University, Berlin, Germany | University of Stuttgart"},{"orgOrder":0,"company":"PIQUR Therapeutics","sponsor":"Hospital Universitario Ramon y Cajal | Hospital Universitari Vall d'Hebron Research Institute | Institut Catal\u00e0 d'Oncologia | Churchill Hospital | Barts Cancer Institute | Fundaci\u00f3n Instituto Valenciano de Oncolog\u00eda","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Bimiralisib","moa":"phosphatidylinositol 3-kinase inhibitors","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"PIQUR Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PIQUR Therapeutics \/ Hospital Universitario Ramon y Cajal | Hospital Universitari Vall d'Hebron Research Institute | Institut Catal\u00e0 d'Oncologia | Churchill Hospital | Barts Cancer Institute | Fundaci\u00f3n Instituto Valenciano de Oncolog\u00eda","highestDevelopmentStatusID":"7","companyTruncated":"PIQUR Therapeutics \/ Hospital Universitario Ramon y Cajal | Hospital Universitari Vall d'Hebron Research Institute | Institut Catal\u00e0 d'Oncologia | Churchill Hospital | Barts Cancer Institute | Fundaci\u00f3n Instituto Valenciano de Oncolog\u00eda"},{"orgOrder":0,"company":"PIQUR Therapeutics","sponsor":"Roswell Park Cancer Institute | MD Anderson Cancer Center | Mayo Clinic | Hospital Clinic of Barcelona | University College London Hospitals | Churchill Hospital | Case Western Reserve University | University Hospital Z\u00fcrich","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Bimiralisib","moa":"phosphatidylinositol 3-kinase inhibitors||PI3K\/mTOR","graph1":"Oncology","graph2":"Phase I","graph3":"PIQUR Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PIQUR Therapeutics \/ Roswell Park Cancer Institute | MD Anderson Cancer Center | Mayo Clinic | Hospital Clinic of Barcelona | University College London Hospitals | Churchill Hospital | Case Western Reserve University | University Hospital Z\u00fcrich","highestDevelopmentStatusID":"6","companyTruncated":"PIQUR Therapeutics \/ Roswell Park Cancer Institute | MD Anderson Cancer Center | Mayo Clinic | Hospital Clinic of Barcelona | University College London Hospitals | Churchill Hospital | Case Western Reserve University | University Hospital Z\u00fcrich"},{"orgOrder":0,"company":"PIQUR Therapeutics","sponsor":"University College London Hospitals | Churchill Hospital | Royal Marsden NHS Foundation Trust | University of Haifa | Weill Medical College of Cornell University | Institut Curie | University Clinical Center Sarajevo | Clinical Center Kragujevac | Clinica","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Bimiralisib","moa":"phosphatidylinositol 3-kinase inhibitors","graph1":"Oncology","graph2":"Phase II","graph3":"PIQUR Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PIQUR Therapeutics \/ University College London Hospitals | Churchill Hospital | Royal Marsden NHS Foundation Trust | University of Haifa | Weill Medical College of Cornell University | Institut Curie | University Clinical Center Sarajevo | Clinical Center Kragujevac | Clinica","highestDevelopmentStatusID":"8","companyTruncated":"PIQUR Therapeutics \/ University College London Hospitals | Churchill Hospital | Royal Marsden NHS Foundation Trust | University of Haifa | Weill Medical College of Cornell University | Institut Curie | University Clinical Center Sarajevo | Clinical Center Kragujevac | Clinica"},{"orgOrder":0,"company":"Torqur","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Bimiralisib","moa":"phosphatidylinositol 3-kinase inhibitors","graph1":"Dermatology","graph2":"Phase II","graph3":"Torqur","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Torqur \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Torqur \/ Undisclosed"},{"orgOrder":0,"company":"Torqur","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Bimiralisib","moa":"phosphatidylinositol 3-kinase inhibitors","graph1":"Dermatology","graph2":"Phase II","graph3":"Torqur","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Torqur \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Torqur \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for Bimiralisib

    Menu

    Bimiralisib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Torqur

                            Switzerland arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Torqur

                            Switzerland arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bimiralisib

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Torqur AG Presents Interim Phase 2 Clinical Trial Results

                            Details : Bimiralisib is a selective pan-PI3K/mTOR inhibitor, which is being evaluated for the topical treatment of actinic keratosis of the face or scalp.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 07, 2025

                            Lead Product(s) : Bimiralisib

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Torqur

                            Switzerland arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Torqur

                            Switzerland arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bimiralisib

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study on the Safety and Efficacy of Bimiralisib Gel in Participants Suffering From Actinic Keratosis

                            Details : Bimiralisib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Keratosis, Actinic.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 20, 2024

                            Lead Product(s) : Bimiralisib

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            PIQUR Therapeutics

                            Country arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            PIQUR Therapeutics

                            Country arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bimiralisib

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : University Hospital, Basel | University Hospital Munich | University Hospital Freiburg | Charite University, Berlin, Germany | University of Stuttgart

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase 2 Study With PQR309 in Relapsed or Refractory Lymphoma Patients

                            Details : PQR309 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Lymphoma.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 25, 2017

                            Lead Product(s) : Bimiralisib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : University Hospital, Basel | University Hospital Munich | University Hospital Freiburg | Charite University, Berlin, Germany | University of Stuttgart

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            PIQUR Therapeutics

                            Country arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            PIQUR Therapeutics

                            Country arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bimiralisib

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            PQR309 in Phase 2 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma

                            Details : PQR309 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Central Nervous System Lymphoma.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 19, 2017

                            Lead Product(s) : Bimiralisib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            PIQUR Therapeutics

                            Country arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            PIQUR Therapeutics

                            Country arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bimiralisib

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : University Hospital, Basel | Insel Gruppe AG, University Hospital Bern | University Hospital Zürich

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamic Effects of PQR309 in Glioblastoma...

                            Details : PQR309 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Glioblastoma.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 01, 2016

                            Lead Product(s) : Bimiralisib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : University Hospital, Basel | Insel Gruppe AG, University Hospital Bern | University Hospital Zürich

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            PIQUR Therapeutics

                            Country arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            PIQUR Therapeutics

                            Country arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bimiralisib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Hospital Universitario Ramon y Cajal | Hospital Universitari Vall d'Hebron Research Institute | Institut Català d'Oncologia | Churchill Hospital | Barts Cancer Institute | Fundación Instituto Valenciano de Oncología

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            PQR309 and Eribulin in Metastatic HER2 Negative and Triple-negative Breast Cancer (PIQHASSO)

                            Details : PQR309 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Breast Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 31, 2016

                            Lead Product(s) : Bimiralisib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Hospital Universitario Ramon y Cajal | Hospital Universitari Vall d'Hebron Research Institute | Institut Català d'Oncologia | Churchill Hospital | Barts Cancer Institute | Fundación Instituto Valenciano de Oncología

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            PIQUR Therapeutics

                            Country arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            PIQUR Therapeutics

                            Country arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bimiralisib

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            PQR309 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma

                            Details : PQR309 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Central Nervous System Lymphoma.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 01, 2016

                            Lead Product(s) : Bimiralisib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            PIQUR Therapeutics

                            Country arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            PIQUR Therapeutics

                            Country arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bimiralisib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Roswell Park Cancer Institute | MD Anderson Cancer Center | Mayo Clinic | Hospital Clinic of Barcelona | University College London Hospitals | Churchill Hospital | Case Western Reserve University | University Hospital Zürich

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of Oral PQR309 in Patients With Advanced Solid Tumors

                            Details : PQR 309 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 29, 2015

                            Lead Product(s) : Bimiralisib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Roswell Park Cancer Institute | MD Anderson Cancer Center | Mayo Clinic | Hospital Clinic of Barcelona | University College London Hospitals | Churchill Hospital | Case Western Reserve University | University Hospital Zürich

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            PIQUR Therapeutics

                            Country arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            PIQUR Therapeutics

                            Country arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bimiralisib

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : University College London Hospitals | Churchill Hospital | Royal Marsden NHS Foundation Trust | University of Haifa | Weill Medical College of Cornell University | Institut Curie | University Clinical Center Sarajevo | Clinical Center Kragujevac | Clinica

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Open-Label, Non Randomized Phase 2 Study With Safety Run-In

                            Details : Bimiralisib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Lymphoma.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 25, 2014

                            Lead Product(s) : Bimiralisib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : University College London Hospitals | Churchill Hospital | Royal Marsden NHS Foundation Trust | University of Haifa | Weill Medical College of Cornell University | Institut Curie | University Clinical Center Sarajevo | Clinical Center Kragujevac | Clinica

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            PIQUR Therapeutics

                            Country arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            PIQUR Therapeutics

                            Country arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bimiralisib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Investigate Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of PQR309

                            Details : PQR309 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 12, 2013

                            Lead Product(s) : Bimiralisib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth